Immunoglobulin heavy variable (IgHV) gene mutation and micro-RNA expression in Burkitt's lymphoma at Moi Teaching and Referral Hospital in Western Kenya.
Burkitt's lymphoma
IgHV
microRNA
somatic hypermutation
Journal
African health sciences
ISSN: 1729-0503
Titre abrégé: Afr Health Sci
Pays: Uganda
ID NLM: 101149451
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
entrez:
5
3
2020
pubmed:
5
3
2020
medline:
30
9
2020
Statut:
ppublish
Résumé
Burkitt's lymphoma (BL) is a virus associated childhood B-cell cancer common in Eastern Africa. Continued survival of B-cells in germinal centres depend on expression of high affinity immunoglobulins (Ig) to complementary antigens by somatic hypermutation of Ig genes. Cellular microRNAs, non-coding RNAs have been reported to play role in cell cycle regulation. Both viral antigen dependent mutation and micro-RNA expression maybe involved in BL pathogenesis. To describe immunoglobulin heavy variable (IgHV) rearrangement and micro-RNA expressions in BL tumours. Genomic DNA were extracted and purified from BL tissue blocks at Moi Teaching and Referral Hospital, before amplification using IgHV consensus primers and sequencing. The sequences were then aligned with germline alleles in IMGT/V-QUEST® database. Total RNA extracted from tissue blocks and cell lines were used to determine relative expression of hsamiR-34a and hsa-miR-127. In all tumours, allele alignment scores and number of mutations range were 89.2-93.2%, 15-24 respectively. The range of IgHV amino acid changes were higher in EBER-1+ (15-25) than EBER-1- (9-15). In MYC+ tumours, the relative expression were: hsa-miR-127(2.09);hsa-miR-34a (2.8) and MYC- hsa-miR-127 (1.2), hsa-miR-34a (1.0). B-cell in BL contained somatic mutated IgHV gene and upregulated cellular microRNAs with possible pathogenetic role(s).
Identifiants
pubmed: 32127902
doi: 10.4314/ahs.v19i4.48
pii: jAFHS.v19.i4.pg3242
pmc: PMC7040314
doi:
Substances chimiques
MicroRNAs
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3242-3248Informations de copyright
© 2019 Ndede et al.
Références
J Clin Pathol. 2003 Mar;56(3):188-92
pubmed: 12610094
Br J Haematol. 2006 Aug;134(3):294-301
pubmed: 16848772
Adv Hematol. 2011;2011:347137
pubmed: 21461378
Leukemia. 2011 Dec;25(12):1869-1876
pubmed: 21701491
PLoS One. 2010 Sep 24;5(9):
pubmed: 20930934
J Pathol. 2008 Dec;216(4):440-50
pubmed: 18802929
Blood Cancer J. 2012 Aug 31;2:e84
pubmed: 22941339
PLoS One. 2011;6(6):e20781
pubmed: 21698185
Afr Health Sci. 2007 Sep;7(3):166-75
pubmed: 18052871
Int J Cancer. 2007 Jan 1;120(1):121-7
pubmed: 17019706
J Oncol. 2010;2010:
pubmed: 20953370
Nat Rev Cancer. 2006 Apr;6(4):259-69
pubmed: 16557279
Int J Mol Sci. 2018 Apr 12;19(4):
pubmed: 29649101
Am J Pathol. 1995 Nov;147(5):1398-407
pubmed: 7485402
J Clin Oncol. 2000 Nov 1;18(21):3707-21
pubmed: 11054444
Blood. 2011 Mar 31;117(13):3596-608
pubmed: 21245480
PLoS One. 2008 Jun 18;3(6):e2505
pubmed: 18560562
Am J Clin Pathol. 2016 Jan;145(1):116-27
pubmed: 26712879
Blood. 2008 Dec 1;112(12):4384-99
pubmed: 19029456
Blood. 2012 Aug 30;120(9):1782-90
pubmed: 22760782
Cancer Lett. 2011 Jun 28;305(2):186-99
pubmed: 20943311
Int J Cancer. 2010 Mar 15;126(6):1316-26
pubmed: 19530237
Blood. 2009 May 7;113(19):4586-94
pubmed: 19202128